Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small cell lung cancer and no other actionable oncogenic driver

Marta Domènech, Ana M. Muñoz Marmol, Jose Luis Mate, Anna Estival, Teresa Moran, Marc Cucurull, Maria Saigi, Ainhoa Hernandez, Carolina Sanz, Alba Hernandez-Gallego, Aintzane Urbizu, Anna Martinez-Cardus, Adrià Bernat, Enric Carcereny*

*Autor corresponent d’aquest treball

Producció científica: Contribució a una revistaArticleRecercaAvaluat per experts

9 Cites (Scopus)

Resum

Non-small cell lung cancers (NSCLC) are the most common type of lung cancer and can be classified according to the presence of mutually exclusive oncogenic drivers. The majority of NSCLC patients present a non-actionable oncogenic driver, and treatment resistance through the amplification of the MET proto-oncogene (MET) or the expression of programmed cell death protein 1 ligand (PD-L1) is common. Herein, we investigated the relation between MET gene amplification and PD-L1 expression in patients with advanced NSCLC and no other actionable oncogenic driver (i.e., EGFR, ALK, ROS1). Our retrospective observational study analyzed data from 48 patients (78% men, median age 66 years) admitted to the Germans Trias i Pujol Hospital, Spain, between July 2015 and February 2019. Patients presenting MET amplification showed a higher proportion of PD-L1 expression (93% vs. 39%; p < 0.001) and overexpression (64% vs. 27%; p = 0.020) than those with non-amplified MET. PD-L1 expression was not significantly different when analyzed by sex (p = 0.624), smoking history (p = 0.429), and Eastern Cooperative Oncology Group Performance Status (p = 0.597) Overall survival rates were not significantly affected by MET amplification (high and intermediate amplification vs low amplification and non-amplificated) (p = 0.252) nor PD-L1 expression (> vs =< 50%) (p = 0.893). In conclusion, a positive correlation was found between MET gene amplification and PD-L1 expression and highly expressed (above 50%) in patients with NSCLC and no other actionable oncogenic driver. It could be translated as new guided-treatment oportunities for these patients.
Idioma originalEnglish
Pàgines (de-a)1802-1810
Nombre de pàgines9
RevistaOncotarget
Volum12
Número18
DOIs
Estat de la publicacióPublicada - 31 d’ag. 2021

Keywords

  • MET amplification
  • Non-small cell lung cancer
  • Oncogenic driver
  • PD-L1

Fingerprint

Navegar pels temes de recerca de 'Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small cell lung cancer and no other actionable oncogenic driver'. Junts formen un fingerprint únic.

Com citar-ho